Hide-and-seek: The interplay between cancer stem cells and the immune system

Carcinogenesis

Volumn 38, Issue 2, 2017, Pages 107-118

  Sultan, Mohammad ^a   Coyle, Krysta Mila ^a   Vidovic, Dejan ^a   Thomas, Margaret Lois ^a   Gujar, Shashi ^a   Marcato, Paola ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT;

CANCER IMMUNOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; MACROPHAGE; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL EXPANSION; TUMOR ESCAPE; TUMOR IMMUNITY; DRUG EFFECTS; DRUG RESISTANCE; IMMUNITY; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY; KILLER CELLS, NATURAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 85019712411     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw115     Document Type: Review

References (108)

1. Ehrlich, P. (1909) über den jetzigen stand der chemotherapie. Ber. Dtsch. Chem. Ges., 42, 17-47.
2. Aitken, W. (1863) The Science and Practice of Medicine. Vol. 2. Lindsay and Blakiston, Philadelphia, PA.
3. Thomas, L. (1959) Discussion. In Lawrence, H.S. (ed). Cellular and Humoral Aspects of the Hypersensitive States. Hoeber-Harper, New York, NY, pp. 529-533.
4. Burnet, M. (1957) Cancer; a biological approach. I. The processes of control. Br. Med. J., 1, 779-786.
5. Burnet, M. (1964) Immunological factors in the process of carcinogenesis. Br. Med. Bull., 20, 154-158.
6. Swann, J.B. et al. (2007) Immune surveillance of tumors. J. Clin. Invest., 117, 1137-1146.
7. Gold, P. et al. (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med., 121, 439-462.
8. Scribner, J.D. et al. (1972) Inflammation and tumor promotion: selective protein induction in mouse skin by tumor promoters. Eur. J. Cancer, 8, 617-621.
9. Dunn, G.P. et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
10. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA, 100, 3983-3988.
11. Ginestier, C. et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-567.
12. Dalerba, P. et al. (2007) Cancer stem cells: models and concepts. Annu. Rev. Med., 58, 267-284.
13. Lapidot, T. et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-648.
14. Bonnet, D. et al. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 3, 730-737.
15. Singh, S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401.
16. Ma, S. et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 132, 2542-2556.
17. O'Brien, C.A. et al. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-110.
18. Hermann, P.C. et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1, 313-323.
19. Li, C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res., 67, 1030-1037.
20. Liu, C. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 17, 211-215.
21. Medema, J.P. (2013) Cancer stem cells: the challenges ahead. Nat. Cell Biol., 15, 338-344.
22. Bruttel, V.S. et al. (2014) Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front. Immunol., 5, 360.
23. Komuro, H. et al. (2007) Identification of side population cells (stemlike cell population) in pediatric solid tumor cell lines. J. Pediatr. Surg., 42, 2040-2045.
24. Schatton, T. et al. (2008) Identification of cells initiating human melanomas. Nature, 451, 345-349.
25. Wouters, J. et al. (2013) The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS One, 8, e76550.
26. Monzani, E. et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer, 43, 935-946.
27. Awad, O. et al. (2010) High ALDH activity identifies chemotherapyresistant Ewing's sarcoma stem cells that retain sensitivity to EWSFLI1 inhibition. PLoS One, 5, e13943.
28. Clay, M.R. et al. (2010) Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck, 32, 1195-1201.
29. Silva, I.A. et al. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res., 71, 3991-4001.
30. Sládek, N.E. et al. (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol., 49, 309-321.
31. Liu, Q. et al. (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J. Neurooncol., 94, 1-19.
32. Bao, S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
33. Loebinger, M.R. et al. (2008) Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br. J. Cancer, 98, 380-387.
34. Coussens, L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860- 867.
35. Condeelis, J. et al. (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263-266.
36. Mantovani, A. et al. (2005) Macrophage polarization comes of age. Immunity, 23, 344-346.
37. Jinushi, M. et al. (2011) Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl Acad. Sci. USA, 108, 12425-12430.
38. Wan, S. et al. (2014) Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology, 147, 1393-1404.
39. Fan, Q.M. et al. (2014) Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett., 352, 160-168.
40. Hou, Y.C. et al. (2014) Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer, 120, 2766-2777.
41. Lu, H. et al. (2014) A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol., 16, 1105-1117.
42. Okuda, H. et al. (2012) Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stemlike cells with macrophages and stromal cells. Cancer Res., 72, 537-547.
43. Tseng, H.C. et al. (2015) Differential cytotoxicity but augmented IFN-γ secretion by NK cells after interaction with monocytes from humans, and those from wild type and myeloid-specific COX-2 knockout mice. Front. Immunol., 6, 259.
44. Tseng, H.C. et al. (2014) Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell-cell contact and secreted factors. Front. Immunol., 5, 269.
45. Gabrilovich, D.I. et al. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 9, 162-174.
46. Lindau, D. et al. (2013) The immunosuppressive tumour network: myeloid- derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105-115.
47. Cui, T.X. et al. (2013) Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity, 39, 611-621.
48. Panni, R.Z. et al. (2014) Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother., 63, 513-528.
49. Banchereau, J. et al. (1998) Dendritic cells and the control of immunity. Nature, 392, 245-252.
50. Lee, C.G. et al. (2012) A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br. J. Haematol., 158, 79-90.
51. Ma, Y. et al. (2013) Dendritic cells in the cancer microenvironment. J. Cancer, 4, 36-44.
52. Tourkova, I.L. et al. (2007) Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J. Immunol., 178, 7787-7793.
53. Tourkova, I.L. et al. (2005) Restoration by IL-15 of MHC class I antigenprocessing machinery in human dendritic cells inhibited by tumorderived gangliosides. J. Immunol., 175, 3045-3052.
54. Shurin, M.R. et al. (2002) Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer, 101, 61-68.
55. Curiel, T.J. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10, 942-949.
56. Wolf, A.M. et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res., 9, 606-612.
57. Yang, S. et al. (2011) Foxp3+IL-17+ T cells promote development of cancer- initiating cells in colorectal cancer. J. Leukoc. Biol., 89, 85-91.
58. Guermonprez, P. et al. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol., 20, 621-667.
59. Ziegler, K. et al. (1981) Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes. J. Immunol., 127, 1869-1875.
60. Chikamatsu, K. et al. (2011) Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck, 33, 208-215.
61. Schatton, T. et al. (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res., 70, 697-708.
62. Di Tomaso, T. et al. (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res., 16, 800-813.
63. Volonté, A. et al. (2014) Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J. Immunol., 192, 523-532.
64. Wei, J. et al. (2010) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther., 9, 67-78.
65. Inoda, S. et al. (2011) Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am. J. Pathol., 178, 1805-1813.
66. Suárez-Alvarez, B. et al. (2010) Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One, 5, e10192.
67. Le Blanc, K. et al. (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol., 31, 890-896.
68. Brahmer, J.R. et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 366, 2455-2465.
69. Lee, Y. et al. (2014) PD-L1 is preferentially expressed on CD44+ tumorinitiating cells in head and neck squamous cell carcinoma. J. Immunother. Cancer, 2, P270.
70. Jinushi, M. (2014) Role of cancer stem cell-associated inflammation in creating pro-inflammatory tumorigenic microenvironments. Oncoimmunology, 3, e28862.
71. Wu, A. et al. (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro. Oncol., 12, 1113-1125.
72. Theocharides, A.P. et al. (2012) Disruption of SIRPa signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J. Exp. Med., 209, 1883-1899.
73. Kuang, D.M. et al. (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol., 54, 948-955.
74. Hira, V.V. et al. (2015) CD133+ and nestin+ glioma stem-like cells reside around CD31+ arterioles in niches that express SDF-1a, CXCR4, osteopontin and cathepsin K. J. Histochem. Cytochem., 63, 481-493.
75. Smyth, M.J. et al. (1999) Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol., 162, 6658-6662.
76. Bauer, S. et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science, 285, 727-729.
77. Vivier, E. et al. (2008) Functions of natural killer cells. Nat. Immunol., 9, 503-510.
78. Tseng, H.C. et al. (2010) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One, 5, e11590.
79. Jewett, A. et al. (2014) Natural killer cells as effectors of selection and differentiation of stem cells: role in resolution of inflammation. J. Immunotoxicol., 11, 297-307.
80. Jewett, A. et al. (2013) Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J. Cancer, 4, 12-24.
81. Chester, C. et al. (2015) Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front. Immunol., 6, 601.
82. Tseng, H.C. et al. (2015) Differential targeting of stem cells and differentiated glioblastomas by NK cells. J. Cancer, 6, 866-876.
83. Cheng, M. et al. (2013) NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol., 10, 230-252.
84. Castriconi, R. et al. (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol., 182, 3530- 3539.
85. Avril, T. et al. (2012) Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol., 22, 159-174.
86. Ames, E. et al. (2015) NK cells preferentially target tumor cells with a cancer stem cell phenotype. J. Immunol., 195, 4010-4019.
87. Wang, B. et al. (2014) Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res., 74, 5746-5757.
88. Tallerico, R. et al. (2013) Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J. Immunol., 190, 2381-2390.
89. Jewett, A. et al. (2012) Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr. Drug Deliv., 9, 5-16.
90. Pietra, G. et al. (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol., 21, 793-801.
91. Fernández, L. et al. (2015) Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett., 368, 54-63.
92. She, M. et al. (2012) Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett., 318, 173-179.
93. Bendelac, A. et al. (2007) The biology of NKT cells. Annu. Rev. Immunol., 25, 297-336.
94. Ni, C. et al. (2015) Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression. Cancer Lett., 356(2 Pt B), 579-588.
95. Massi, D. et al. (2014) PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann. Oncol., 25, 2433-2442.
96. Chen, B.J. et al. (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res., 19, 3462-3473.
97. Wolchok, J.D. et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 369, 122-133.
98. Zhi, Y. et al. (2015) B7H1 expression and epithelial-to-mesenchymal transition phenotypes on colorectal cancer stem-like cells. PLoS One, 10, 1-15.
99. Yang, Y. et al. (2015) B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. Oncol. Lett., 9, 1833-1838.
100. Lee, Y. et al. (2016) CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin. Cancer Res., 22, 3571-3581.
101. Gupta, H.B. et al. (2016) Tumor B7-H1 regulates cancer stem cell generation and virulence. J. Immunol., 196 (suppl. 1), 72.3.
102. Xie, T.X. et al. (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene, 23, 3550-3560.
103. Wei, D. et al. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 22, 319-329.
104. Wong, A.L. et al. (2015) Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol., 26, 998-1005.
105. Rosenberg, S.A. et al. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 10, 909-915.
106. Xu, Q. et al. (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells, 27, 1734-1740.
107. Dhodapkar, M.V. et al. (2011) Vaccines targeting cancer stem cells: are they within reach? Cancer J., 17, 397-402.
108. Zhao, F. et al. (2015) Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases. Am. J. Transl. Res., 7, 1870-1882.